3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Endometrial Neoplasms
5
Ovarian Neoplasms
4
Sarcoma
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Endometrial Stromal
1
Recurrence
1
Primary Myelofibrosis
1
Neurofibrosarcoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Leiomyosarcoma
1
Genital Diseases
1
Fallopian Tube Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
13
pembrolizumab
8
Carboplatin
7
Surveys and Questionnaires
6
Cisplatin
6
Brachytherapy
5
Doxorubicin
4
Docetaxel
4
Pemetrexed
3
Hyperthermic Intraperitoneal Chemotherapy
3
Gemcitabine
3
FANG vaccine
3
Biopsy
3
osimertinib
2
olaparib
2
niraparib
2
durvalumab
2
adavosertib
2
Trastuzumab
2
Topotecan
2
Taxes
2
Standard of Care
2
Sentinel Lymph Node Biopsy
2
Saline Solution
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Nivolumab
2
Music Therapy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
selinexor
×
Gynecologic
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled